Gold bars to be exempt from tariffs, White House clarifies
Thursday
H.C. Wainwright has reaffirmed its Neutral rating on Xenetic Biosciences (NASDAQ:XBIO) stock following a featured segment on the company's recent preclinical data. The segment, part of a "What This Means" series, spotlighted commentary from Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic. Dr. Bissonnette discussed the potential benefits of combining DNase I with CAR T cells in the treatment of melanoma lung metastasis in a mouse model.
The preclinical data, which had been previously presented, suggests that DNase I could play a crucial role in enhancing the efficacy of CAR T cell therapies for solid tumors, which have traditionally faced challenges such as immune cell infiltration and function due to the tumor's physical and immunosuppressive barriers. While the company maintains a strong financial position with a current ratio of 7.37 and more cash than debt on its balance sheet, InvestingPro data indicates significant stock price volatility with a beta of 2.31. According to Dr. Bissonnette, solid tumors, unlike blood cancers, are characterized by dense architecture and abnormal vasculature that limit immune response. Neutrophil extracellular traps (NETs) are particularly problematic, as they obstruct immune cell movement and reduce CAR T cell activity within the tumor.
Xenetic's approach involves using DNase I to degrade NETs, potentially reducing the barriers that prevent CAR T cells from effectively targeting tumor cells. The strategy is to administer DNase I systemically to improve the activity of CAR T cells. The preclinical study showed encouraging results in a melanoma lung metastasis model, supporting the company's broader development plans.
The segment served to highlight the importance of these findings and how they integrate into Xenetic's overall strategy for developing cancer treatments. Despite the promising nature of the preclinical data, H.C. Wainwright has chosen to maintain a Neutral rating on Xenetic Biosciences stock, signaling a cautious stance on the company's prospects at this stage of research. InvestingPro subscribers have access to 8 additional key insights about XBIO, including detailed financial health metrics and growth projections that could help inform investment decisions in this volatile biotech stock.
In other recent news, Xenetic Biosciences, Inc. has announced a new clinical study in collaboration with PeriNess Ltd. The study will be conducted at the Tel-Aviv Sourasky Medical (TASE:BLWV) Center and will focus on patients with relapsed/refractory osteosarcoma and Ewing sarcoma. Led by Prof. Ronit Elhasid, the study aims to evaluate the safety, tolerability, and efficacy of Xenetic's systemic DNase I candidate, XBIO-015, in combination with chemotherapy. The primary goal is to assess the treatment's safety, with secondary objectives including measuring the objective response rate and progression-free survival. This initiative is part of Xenetic's broader strategy to expand clinical data for its DNase program. The company aims to explore the potential of XBIO-015 across various oncology indications. Previously, Xenetic and PeriNess had agreed to conduct studies on recombinant DNase for pancreatic carcinoma and other solid tumors in Israel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.